Recursion

Highly Engaged Employees

Recursion is a clinical-stage biotechnology company founded in 2013 that specializes in decoding biology through the integration of technological innovations. By leveraging automation, machine learning, and advanced engineering, the firm aims to industrialize drug discovery. The company utilizes the Recursion Operating System, which combines a massive proprietary biological and chemical dataset with the Recursion Map, a suite of custom algorithms designed to navigate foundational biology without human bias.

Operating with 500-1,000 employees across 4 locations, Recursion maintains a robust organizational structure focused on scaling its biopharmaceutical pipeline. The company’s commitment to innovation is reflected in its diverse workforce of scientists and engineers. Meet Recursion's team to learn about their leadership and the technical expertise driving their clinical-stage drug discovery efforts.

Recursion, traded under the ticker NASDAQ: RXRX, reported annual revenue of $66.4M. The company has secured significant capital through multiple funding rounds, including a notable $50.0M investment from NVIDIA in 2023. These financial resources support the ongoing development of their proprietary infrastructure and the expansion of their drug discovery capabilities. Explore financial highlights for detailed metrics regarding their market performance and funding history.